A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Trial details
- Registry ID
- NCT06346067
- Drugs studied
- Dacarbazine, Naporafenib, Temozolomide, Trametinib
TrialRedline tracks 1 clinical trial sponsored by Erasca, Inc.: 1 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067 | Dacarbazine, Naporafenib, Temozolomide, Trametinib | Active not recruiting | 2028-04Estimated |
Names as written in the registry records.
Before: Estimated. After: Actual.
Before: 470 participants (planned). After: 78 participants (actual).
Before: Recruiting. After: Active not recruiting.